The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Keytruda or pembrolizumab, the company's anti-PD-1 therapy, for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma or cHL. This is the fourth Breakthrough Therapy Designation granted for Keytruda. The granting of this designation is based on data from the ongoing Phase Ib and Phase II keynote trials evaluating the use of Keytruda in patients with Hodgkin lymphoma. The work in this disease area forms part of MSD’s wider development program for this drug, which is being tested in patients with head and neck cancer, non-small cell lung cancer, and multiple myeloma, among others. The Keytruda clinical development programme includes patients with more than 30 tumor types in more than 250 clinical trials, including more than 100 trials that combine Keytruda with other cancer treatments. Registration-enabling trials of Keytruda are currently enrolling patients in melanoma, NSCLC, head and neck cancer, bladder cancer, gastric cancer, colorectal cancer, esophageal cancer, breast cancer, ovarian cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and other tumors, with further trials in planning for other cancers.